Home › Companies › SCYX

Pipeline (5 active programs)

Technology platforms

Capital (as filed)

Cash

$8.2M cash and cash equivalents · Sep 30, 2026 (10-Q)

Short-term investments

$38.9M Sep 30, 2026

Operating cash flow

−$7.5M quarter Jun 30, 2026 → Sep 30, 2026, year-to-date difference (10-Q)

As stated in coverage

$63.2M cash, runway into 2029 per the update of Nov 5, 2026 — the company's own words as read there, not the filed figure

Offering documents (1)

• 2026-11-05 S-3 · Shelf registration up to $200M aggregate

Cash, investments and operating cash flow are the company's own XBRL facts as filed with the SEC, each shown with its period end and tag. As-stated figures come from the company's own words as read in Biotech Distilled coverage, dated, and routinely count securities and planned financing that a balance sheet does not. Offering rows are the SEC cover pages as filed. Not investment advice. Figures as of Nov 7, 2026.

Biotech Distilled coverage (5)

• 2026-11-06 UPDATE: Scynexis (SCYX) - Back Below Cash
• 2026-09-29 UPDATE: Scynexis (SCYX) - BARDA Funds the Antifungal 🔒 Paid
• 2026-08-13 UPDATE: Scynexis (SCYX) - Adage Shows Up 🔒 Paid
• 2026-08-11 UPDATE: Scynexis (SCYX) - The Negative Enterprise Value Just Evaporated 🔒 Paid
• 2026-06-24 Scynexis, Inc. (SCYX) - Scientific Deep Dive for SCY-770 (ADPKD) and Pipeline Products 🔒 Paid

Articles open on Substack. Some are subscriber-only; those marked ★ Distilled Pro are for Distilled Pro members.

Verdict history (5 calls)

Every verdict Biotech Distilled has published on Scynexis, oldest first — the full history, never a selection. How calls are scored: the track record.

1. 2026-06-24 Watch Scynexis, Inc. (SCYX) - Scientific Deep Dive for SCY-770 (ADPKD) and Pipeline Products A credible orphan target and below-cash balance sheet keep it off the PASS pile, but a distressed-seller re-skin with no human ADPKD efficacy entering Phase 2 behind Novartis, Vertex, and AbbVie does not warrant ownership until the 2H 2027 htTKV readout proves the mechanism.
2. 2026-08-11 Watch UPDATE: Scynexis (SCYX) - The Negative Enterprise Value Just Evaporated The negative-enterprise-value cushion has compressed from ~$30M to ~$20M as the stock ran 35% on thin-tape mechanics, and 8.26M dilutive securities are now live, making the entry math meaningfully worse while the mechanism remains unproven in a human kidney.
3. 2026-08-13 Watch UPDATE: Scynexis (SCYX) - Adage Shows Up Adage Capital filing a 9.99% stake narrows the sponsorship gap in the bear case, but roughly half the position is $9.60 warrants and the ADPKD mechanism remains entirely unproven in humans until the 2H 2027 htTKV readout.
4. 2026-09-29 Watch UPDATE: Scynexis (SCYX) - BARDA Funds the Antifungal BARDA's up-to-$214M contract funds SCY-247 into Phase 2 without touching the ADPKD runway, upgrading the second program from unfunded placeholder to funded option, but the equity story still rests entirely on SCY-770's unproven 2027 kidney readout.
5. 2026-11-06 Watch UPDATE: Scynexis (SCYX) - Back Below Cash The stock is back at roughly half of net cash with both Phase 1 gates cleared and real kidney expertise on staff, but an ~$8M quarterly burn strains the 2029 runway, a financing toolkit (shelf + ATM) signals likely dilution before the Q4 2027 binary, and the mechanism remains unproven in a human kidney.

Every verdict Biotech Distilled has published on this company, in order, with the post it came from — the full history, never a selection. Position figures are the same ones shown on /track-record, computed by the same method. Editorial opinion, not investment advice.

Timing, in the company's words (1 quote from 1 filing)

Sentences quoted verbatim from the company's SEC filings, newest filing first. Each sits under the filing it appeared in; the "matched to" tag names the calendar row it was read for.

• 2026-08-10 10-Q in filings ↓

  • “initiating a Phase 2 proof-of-concept clinical study in ADPKD patients during the fourth quarter of 2026; and”

    matched to SCY-770 · trial initiation · read as fourth quarter of 2026

Timing sentences quoted from the company's own SEC filings, each under the filing it appeared in. The 'matched to' tag is the calendar row the sentence was read for; the filing is the source. Not investment advice.

Filings & releases (32)

SEC filings from EDGAR and press releases captured from the company's investor-relations site, newest first. Releases captured from Aug 10, 2026; filings from March 2026. Summaries come from the BD update that read the document; "BD extracted" counts point at the pipeline table above. All companies →

• Nov 5, 2026S-3Shelf registration→ BD updateSummary on the 10-Q
• Nov 5, 2026ReleaseSCYNEXIS Reports Third Quarter 2026 Financial Results and Provides Corporate Update→ BD updateSummary on the 10-Q
• Nov 5, 202610-QQuarterly report→ BD updateThe Phase 1 SCY-770 gating study is done, the Phase 2 clock is ticking, and SCYX just hired a nephrologist to run R&D — but the stock is down 14% on the day, and the market is reading the S-3 shelf renewal as a capital-raise signal.
• Oct 29, 2026ReleaseSCYNEXIS to Participate in the 3rd Annual Guggenheim Healthcare Innovation Conference
• Oct 22, 2026ReleaseSCYNEXIS Completes Phase 1 Study of Intravenous SCY-247, a Novel, Triterpenoid Antifungal in Development for Treatment and Prevention of Invasive Fungal DiseasesThe IV SCY-247 Phase 1 that I flagged as nearly slipping in the September update just cleared cleanly — 50 mg QD hits the murine-model efficacy target, no serious adverse events, and Phase 2 is now slated for 2027 with both oral and IV formulations fully Phase 1-complete under the BARDA umbrella.BD extracted 1 program update from this document → SCYX pipeline
• Oct 21, 2026ReleaseSCYNEXIS to Feature SCY-247 in a Pipeline Presentation at IDWeek
• Oct 6, 2026ReleaseSCYNEXIS Announces Phase 1 Study Results for SCY-770, a Novel, Highly Selective, Oral Direct AMPK Activator for the Treatment of Autosomal Dominant Polycystic Kidney Disease (ADPKD)The SCY-770 Phase 1 gate just cleared: well tolerated at higher doses (750mg QD, 500mg BID), PK characterized, and Phase 2 ADPKD initiation confirmed on track for Q4 2026 — the last logistical hurdle before the real binary is removed.BD extracted 1 program update from this document → SCYX pipeline
• Sep 28, 2026ReleaseSCYNEXIS Awarded BARDA Contract Providing Up to $214 Million in Non-Dilutive Funding for the Development of SCY-247→ BD updateSummary on the 8-K
• Sep 28, 20268-KCurrent report: material agreement, Reg FD disclosure · EX-99.1→ BD updateBARDA just handed SCYNEXIS up to $214M in non-dilutive funding to advance SCY-247 — the antifungal asset I called "optionality, not a value driver, until a partner or grant appears." The grant appears.
• Sep 22, 2026ReleaseSCYNEXIS Appoints Seasoned Industry Veteran Steven K. Burke, M.D., to its Board of Directors
• Sep 22, 20268-KCurrent report: officer / director change, Reg FD disclosure · EX-99.1BD extracted 2 program updates from this document → SCYX pipeline
• Sep 15, 2026ReleaseSCYNEXIS Appoints Todd Minga, M.D., as Senior Vice President, Research & Developmentvia aggregatorA career nephrologist with Akebia/Maze Therapeutics pedigree just took the R&D helm at SCYX — the third piece of the credibility gap closing since the deep dive, and the most operationally significant for an ADPKD-pivoting company with no kidney-disease data yet.
• Sep 15, 2026ReleaseSCYNEXIS Appoints Todd Minga, M.D., as Senior Vice President, Research & DevelopmentSummary on the release
• Sep 10, 2026ReleaseSCYNEXIS Announces Appointment of Sanjay Subramanian as Chief Financial Officer
• Sep 10, 20268-KCurrent report: officer / director change, other events · EX-99.1
• Sep 1, 2026ReleaseSCYNEXIS to Participate in Upcoming Investor Conferencesvia aggregator
• Aug 10, 2026ReleaseSCYNEXIS Reports Second Quarter 2026 Financial Results and Provides Corporate Updatevia aggregatorBD extracted 1 program update from this document → SCYX pipeline
• Aug 10, 202610-QQuarterly reportBD extracted 1 program update from this document → SCYX pipeline
• Jun 26, 20268-KCurrent report: charter / bylaws / fiscal year, shareholder vote, other events
• May 29, 20268-KCurrent report: charter / bylaws / fiscal year
• May 22, 20268-KCurrent report: shareholder vote, other events
• May 11, 202610-QQuarterly report
• May 8, 2026424B3Prospectus (resale / update)
• May 1, 2026S-3Shelf registration
• Apr 30, 2026DEFA14AProxy soliciting material
• Apr 30, 2026DEF 14AProxy statement
• Apr 27, 2026DEF 14AProxy statement
• Apr 20, 20268-KCurrent report: officer / director change
• Mar 31, 20268-KCurrent report: Reg FD disclosure · EX-99.1
• Mar 31, 20268-KCurrent report: material agreement, unregistered sale of equity, Reg FD disclosure · EX-99.1
• Mar 31, 20268-KCurrent report: material agreement, acquisition / disposition, Reg FD disclosure · EX-99.1
• Mar 4, 202610-KAnnual report